

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

TOWNSEND and TOWNSEND and CREW LLP

By:

Susan J. Johnson

PATENT
Attorney Docket No.: 015270-012100US
Client Reference No.: 128 US CON 4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lisa C. McConlogue et al.

Application No.: 10/609,143

Filed: June 27, 2003

For: TRANSGENIC ANIMALS
HARBORING APP ALLELE HAVING
SWEDISH MUTATION

Confirmation No.: 6715

Examiner: Crouch, D.

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08B form are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

The references are obtained from an opposition against a corresponding European patent, EP 730 643. Other references from the opposition have been cited previously. Appended

to document AG is a part of a document from earlier in the proceedings titled "Annex 1: list of cited documents" which provides correspondence between D numbers and reference citations for references referred to in AG. The complete record of the opposition to date can be viewed online (<http://ofi.epoline.org/view/GetDossier>) or can be provided on request.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf
60833289 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/609,143
				Filing Date	June 27, 2003
				First Named Inventor	McLonlogue, Lisa C.
				Art Unit	1632
				Examiner Name	Crouch, D.
Sheet	2	of	2	Attorney Docket Number	015270-012100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	Priority Document for PCT/US93/01817, US application 07/965,971 filed 10/26/92.	<input type="checkbox"/>
	AB	Declaration of Dora Games in Opposition to European Patent 730 643.	<input type="checkbox"/>
	AC	GAMES et al., "Evidence of Altered APP Processing Following Acute Head Trauma in the Rodent," <u>Society For Neuroscience Abstracts</u> , 18(20):1437, abstract 601.2 from 22nd annual meeting held in Anaheim, CA on 10/25-30/92.	<input type="checkbox"/>
	AD	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	<input type="checkbox"/>
	AE	KAWABATA, S., "Alzheimer's retraction," <u>Nature</u> , 356:23 (1992).	<input type="checkbox"/>
	AF	MCCONLOGUE et al., "Transgenic Mice Expressing Human Alzheimer's B-Amyloid Precursor Protein Product High Amounts of B-Peptide," <u>Neurobiology of Aging</u> , 15(suppl. 1):S12, abstract 49 from 4th Int. Conf. on Alzheimer's Disease and Related Disorders, held 7/29-8/3/94 in Minneapolis, MN	<input type="checkbox"/>
	AG	Minutes of Oral Proceedings in Opposition to European application 94931891.9 (5/8/06).	<input type="checkbox"/>
	AH	Online European Patent Register - Results for European application number 19940913347 (8/26/02).	<input type="checkbox"/>
	AI	SELKOE, D. J., "In The Beginning....," <u>Nature</u> , 354:432-433 (1991).	<input type="checkbox"/>
	AJ	TERAI et al., "β-Amyloid Deposits in Transgenic Mice Expressing Human β-Amyloid Precursor Protein Have the Same Characteristics as Those in Alzheimer's Disease," <u>Neuroscience</u> , 104(2):299-310 (2001).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.